News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Lundbeck Says CEO Resigns, Strategy Unchanged
March 5, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COPENHAGEN, March 5 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO: Quote, Profile, Research) said its President and Chief Executive, Claus Braestrup, resigned on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
People
Europe
Lundbeck
MORE ON THIS TOPIC
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
·
2 min read
·
Tristan Manalac
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Manufacturing
Jubilant draws FDA rebuke for delayed mold investigation and quality unit lapses
June 24, 2026
·
2 min read
·
Nick Paul Taylor
